Associatie tussen de ziekte van Graves en thymushyperplasie.

No registrations found.

Ethical review	Positive opinion
Status	Recruiting
Health condition type	-
Study type	Observational non invasive

Summary

ID

NL-OMON25605

Source
NTR

Health condition

Immunodeficiencies

Sponsors and support

Primary sponsor: Erasmus Medical Center, Rotterdam, The Netherlands
Source(s) of monetary or material Support: Erasmus Medical Center, Rotterdam, The Netherlands

Intervention

Outcome measures

Primary outcome

Occurrence of thymic hyperplasia in patients with Graves' disease,
presence of thymic hyperplasia will be analysed with I123 scan 20min and
24hours after intake of I123.

Outcomes will be compared with a database of healthy people, which is already present.

Secondary outcome

Secondary endpoints consist of a change in thymic output, peripheral cell numbers or ratio’s of peripheral T cell
subpopulations in comparison to healthy controls.

Study description

Background summary

Graves' disease is associated with thymic hyperplasia. Since it is known that the TSH receptor is also present in the thymus, stimulating antibodies against the TSH receptor could play a role in thymic hyperplasia. The aim of this study is to investigate how often thymic hyperplasia is present in Graves' disease. Moreover we will investigate if thymic hyperplasia in Graves' disease is caused by stimulation of T cell development in the thymus. 30 patients with Graves' disease who will be treated with radioactive iodine therapy will be recruited on the nuclear medicine department. After the radioactive iodine scan according to the regular treatment, an extra scan will be made from the thymus. Moreover blood samples of these patients will be taken to analyse the t cell pool.

Study objective

Antibodies to the TSH receptor which are produces in Graves' disease can enhance T cell development.

Study design

T0 blood sample;

T1 scan 20 min after radioactive iodine;

T2 scan 24h after radioactive iodine.

Intervention

N/A

Contacts

Public
Dr. Molewaterplein 50-60
Kim Weerd, van der
Rotterdam 3015 GE
The Netherlands
+31 (0)10 7044651
Scientific
Dr. Molewaterplein 50-60
Kim Weerd, van der
Rotterdam 3015 GE
The Netherlands
+31 (0)10 7044651

Eligibility criteria

Inclusion criteria

1. Graves' disease;

2. 18-40 years of age.

Exclusion criteria

1. Use of corticosteroids last three months;

2. Infections during last three months;

3. Thymectomy;

4. Pregnancy;

5. Alcohol abuse.

Study design

Design

Study type:	Observational non invasive
Intervention model:	Crossover
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	15-07-2009
Enrollment:	30
Type:	Anticipated

Ethics review

Positive opinion

Date:	04-12-2009
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

ID: 35294
Bron: ToetsingOnline
Titel:

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL2018

Register	ID
NTR-old	NTR2135
CCMO	NL22657.078.08
ISRCTN	ISRCTN wordt niet meer aangevraagd.
OMON	NL-OMON35294

Study results

Summary results
N/A